Int Immunopharmacol. 2026 Nov 14;191(Pt 2):117675. doi: 10.1016/j.intimp.2026.117675. Online ahead of print.
ABSTRACT
TREM1 and TREM2 are related innate immune receptors involved in inflammatory responses, myeloid-cell function, and tissue remodeling across musculoskeletal disorders (MSDs). Their effects are context dependent and may be considered within a functional TREM1-TREM2 axis. TREM1 primarily amplifies innate inflammatory signaling through DAP12-associated pathways, promoting cytokine and chemokine production, leukocyte activation, and tissue injury. TREM2 regulates phagocytosis, efferocytosis, lipid metabolism, cellular adaptation, and tissue remodeling, but is not uniformly protective: physiological TREM2-DAP12 signaling supports osteoclast differentiation and bone remodeling, whereas enhanced or dysregulated activity may promote osteoclastogenesis, pathological bone resorption, osteoarthritis progression, or abnormal new bone formation. Complete TREM2 deficiency can also disturb tissue and bone homeostasis. This review examines TREM1 and TREM2 in osteoarthritis, rheumatoid arthritis, osteoporosis, and sarcopenia, with emphasis on their cellular functions, disease-specific effects, pharmacological modulators, and potential therapeutic interactions. We also discuss whether disease-, cell-, and stage-specific modulation, potentially coordinated over time or combined with specialized pro-resolving mediators (SPMs), could inform future therapeutic strategies.
PMID:43033542 | DOI:10.1016/j.intimp.2026.117675